

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12N 5/00, 15/00, 7/00		A1	(11) International Publication Number: WO 89/09816 (43) International Publication Date: 19 October 1989 (19.10.89)
(21) International Application Number: PCT/US89/01526 (22) International Filing Date: 12 April 1989 (12.04.89) (30) Priority data: 180,548 12 April 1988 (12.04.88) US 201,762 2 June 1988 (02.06.88) US (71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). (72) Inventors: McKAY, Ronald, D., G. ; 3 Gorham Avenue, Brookline, MA 02146 (US). JAT, Parmjit, S. ; Flat G, 12-15 Rhiedol Terrace, Islington, London N1 (GB). LAMAZAN, Guillermina ; 351 Harvard Street, Cambridge, MA 02138 (US).		(74) Agents: GRANAHAH, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: METHOD FOR MANIPULATION OF THE CELL TYPES OF EUKARYOTES



(57) Abstract

A novel method of immortalizing cell lines, as well as cell lines immortalized by the method. According to the method of the present invention, a gene which confers on a cell the ability to grow in tissue culture is introduced, using known techniques, into such a cell. This gene, referred to as a growth promoting gene, is under external control such that when the gene action or function is turned down or off, the cell in which it resides switches to a new differentiated state. In one embodiment, the temperature sensitive (ts) form of the oncogene derived from the simian virus SV40 is the growth-promoting gene.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

METHOD FOR MANIPULATION OF THE CELL
TYPES OF EUKARYOTES

Description

Background

05 The mechanisms which generate differences between
cell types are poorly understood. Every tissue in a
eukaryote is made up of a mixture of cell types. The
intrinsic molecular properties of these cell types and
the interaction between cells give rise to the
10 specialized functions played by each tissue in an
organism. A wide range of newly developed methods are
now employed to study the biochemistry of cellular
differentiation in eukaryotes.

 Many cell types can be taken from animals and grown
15 in tissue culture for a short period of time. However,
these primary cells have a limited lifespan in culture.
The methods currently available for growing animal cells
indefinitely in culture generally rely on tumor-derived
cells, or on transformation of primary cells involving
20 heritable changes which alter the growth state of the
cells. The usefulness of permanently transformed cells
may be limited because of characteristics introduced by
the transformation process. It would be useful to have a
means of producing or growing quantities of normal cells
25 with defined characteristics.

Summary of the Invention

 The present invention relates to a method of
producing conditionally immortalized continuous cell

-2-

lines from preselected progenitor or precursor cells from vertebrates. The invention also relates to a method of deriving differentiated cells from the conditionally immortalized cell lines. In addition, the invention
05 relates to recombinant retroviruses useful in the present invention.

According to the method of the present invention, a gene which confers the ability to grow continuously in culture is introduced, using known techniques, into a
100 vertebrate cell. The function of the growth promoting, or immortalizing gene is controlled by an external factor or factors so that the gene's function or action may be regulated at will. When the immortalizing gene is altered in its function or action, the cell in which it
15 resides switches to a differentiated state. According to the method of the present invention, large quantities of selected precursor cells can be grown and then induced to differentiate into a pre-selected derivative cell type.

In one embodiment of this invention, the growth
20 promoting gene is a temperature sensitive (ts) mutant of the T antigen from the simian virus SV40 (tsA58). In this embodiment, the temperature sensitive mutant T antigen is introduced into normal neuroepithelial precursor cells, which are then maintained under
25 conditions permissive for continuous growth and expansion of the cell population. Permissive conditions include a temperature at which the mutant SV40 T antigen functions to immortalize cell lines (in this case 33°C). When the cell population has reached the desired size, the
30 temperature is shifted to one at which the growth promoting activity of the mutant SV40 gene is inactivated

-3-

(39°C). In the absence of the growth promoting activity of the immortalizing gene the cells are induced to differentiate.

05 This invention therefor provides a general method for generating from selected precursor cells continuous cell lines which are capable of proliferation and subsequent differentiation.

Brief Description of the Drawing

10 Figure 1 is a schematic representation of the plasmid pZipSV40tsA58, in which the genomic BglI-Hpa I fragment (nucleotides 5235-2666) derived from the early region of the SV40 mutant tsA58 was inserted into the shuttle vector pZipNeoSV(X)1 (Cepko, C. et al., Cell, 1984) with Bam HI linkers.

15 Figure 2 is a schematic representation of the construction of plasmid pZiptsa58U19. Figure 2A is a schematic representation of plasmid pZipNeoSV(X)1 (Cepko, C. et al., Cell, 1984). Figure 2B is a schematic representation of the hybrid of the SV40 T antigen gene, 20 U19, which was constructed using the pZiptsa58 and the U19 mutant.

Detailed Description of the Invention

25 The present invention relates to a novel method of immortalizing cell lines of selected progenitor cells, as well as to cell lines immortalized by the method and to recombinant retroviruses which include a growth promoting gene under external control, such as the temperature sensitive SV40 oncogene. In general, the method comprises introducing into cells of a selected type, in

-4-

primary culture, a growth promoting gene, which enables the cells to grow continuously, and whose function is controlled by an external factor. The primary cells have been previously identified as representing proliferating precursor or progenitor cells. A second gene encoding a selectable marker (e.g., drug resistance) is also introduced into the cells, thereby making it possible to select cells which contain the growth promoting gene. Cells containing both the selectable marker and the growth promoting gene are selected (e.g., by plating onto media containing the drug against which the gene confers resistance) and isolated. It is to be understood that it is unnecessary to introduce a gene encoding a selectable marker if there are other means available for identifying and isolating the cells containing the growth promoting gene. The isolated cells are subsequently plated onto an appropriate medium, under conditions (e.g., temperature) under which the growth promoting function of the gene is activated (e.g., permissive conditions). After allowing sufficient time for the cells to proliferate, the conditions (e.g., temperature) are switched to nonpermissive conditions (e.g., increased temperature) to inactivate the growth promoting gene. Inactivation of the growth promoting gene allows the cells to differentiate.

In a particular embodiment of the present invention, the vertebrate cells are neuronal precursor cells and the temperature sensitive T antigen of SV40 tsA58 is the growth promoting gene. The temperature sensitive domain of the growth promoting gene was inserted into a recombinant retroviral vector by homologous recombination

-5-

with a wild-type SV40 T antigen resident in the vector. Infection with the retroviral vector harboring the mutant T antigen made it possible to introduce the temperature sensitive growth promoting gene with high efficiency into
05 primary cells. Tegtmeyer, P. et al., Journal of Virology, 16:168-178 (1975).-

Primary cells used in the work described below and in the Examples were cells from the nervous system of a mammal. However, it is to be understood that the method
10 of the present invention can be used to immortalize any type of vertebrate cell of interest. In addition, although the description of the method of the present invention makes specific reference to the use of a retroviral vector for introduction of a growth promoting
15 gene which is an oncogene, it is to be understood that other known methods of gene transfer (e.g., electroporation, microinjection) can also be used for this purpose. It is also to be understood that the growth promoting gene can be any gene which effects
20 immortalization or continuous growth of the cell type of interest. It is also possible to introduce conditionally immortalized cells into animals (e.g., mammals) and thereby produce transgenic animals in which the growth promoting gene is inactive at normal body temperatures.
25 Because the ts or otherwise conditionally immortalized cells are present in such animals at the nonpermissive temperature, the precursor cells should be able to differentiate in vivo.

The method of the present invention has been carried
30 out in cells from the developing vertebrate nervous

-6-

system. Monoclonal antibodies have been generated which recognize the major cell types in the embryonic rat central nervous system (CNS). S. Hockfield and R.D.G. McKay, J. Neurosci, 5:3310-3328 (1985). Quantitative methods to determine the number of cells in the rat CNS on each day of embryonic development have also been developed. Knowledge of the number and types of cells, combined with methods which identify proliferating cells, allows identification of a neuroepithelial cell population with properties expected of a progenitor or precursor cell. K. Frederiksen and R.D.G. McKay, J. Neurosci, 8:1144-1151 (1988).

Because the cell types present in the developing brain had previously been characterized, it was possible to verify that differentiated cells produced by the method do, in fact, have the characteristics of neurons or glia. K. Frederiksen and R.D.G. McKay, J. Neurosci, 8:1144-1151 (1988); S. Hockfield and R.D.G. McKay, J. Neurosci, 5:3310-3328 (1985). This ability to characterize the cell types allows direct verification of the ability of the present method to produce a continuous cell line from which pre-selected differentiated derivatives can be produced through control of the growth promoting gene.

In the examples, two regions of the embryonic rat nervous system were chosen as sources of primary cells: the hippocampus and the cerebellum. Primary cells were plated in tissue culture and exposed to a synthetic retrovirus (see Example 1) carrying the temperature sensitive form of SV40 T antigen. The retrovirus also contains a gene encoding drug resistance (i.e., G418

-7-

resistance), which served as the basis for selecting cells containing the retrovirus. Immortal cell lines expressing SV40 T antigen were obtained from these cultures by growing the cells at 33°C in drug-containing medium. Those cells containing the G418 resistance gene (Neo) grew in the drug-containing medium; those lacking the gene did not survive. At 33°C, the surviving cells grew with the standard morphology of continuous cell lines. Clonal cells were obtained by picking colonies using cloning rings. The cells were then tested for their response to growth at 39°C, the nonpermissive temperature for tsA58 T antigen. The criteria evaluated for cellular response were morphology, immunohistochemistry and immunochemistry. The method used and the data obtained are described in detail in the Examples and demonstrate that when the temperature is raised, cells can differentiate to a cell type characteristic of neurons and glia. The methods used in verifying that the resulting differentiated cells have such characteristics are also described in the Examples.

A continuous precursor cell line which differentiates into mature oligodendrocytes has also been produced, using an approach similar to that described above. Oligodendrocytes, the myelin-forming cells of the CNS, develop during the first week of postnatal life in the optic nerve of the rat. Oligodendrocyte progenitors are bipotential cells which also give rise to type 2 astrocytes. To obtain permanent cell lines, primary cultures from the optic nerve of 3-day-old Sprague Dawley (SD) rats were infected with a retrovirus vector transducing the SV40 tsA58/U19 large T antigen (E.

-8-

Paucha, et al., J. Virol., 57: 50-64 (1986). At the permissive temperature, one of the derived cell lines proliferates and expresses the T antigen and small amounts of GC (galactocerebroside), a surface lipid marker for oligodendrocytes and A₂B₅ (surface gangliosides). At the non-permissive temperature, the cells lose the T antigen expression, stop proliferating, and stain very strongly with GC and A₂B₅ antibodies. The two main protein components of myelin, MBP (myelin basic protein) and PLP (proteolipid protein) are also expressed. A₂B₅ and GC are selectable markers which are highly specific for either precursor or mature oligodendrocytes (e.g., GC is a lipid present only on oligodendrocytes). MB and PLP are two myelinating oligodendrocyte markers. Use of these selectable markers resulted in highly specific selection of an oligodendrocyte precursor which differentiates into mature oligodendrocytes when the immortalizing gene is inactivated (in this case, by shifting the temperature at which the cells were being maintained to the nonpermissive temperature, 39°C). Construction of this cell line is described in Example 3. An oligodendrocyte optic nerve cell line (ts U195) was deposited (June 1, 1988) at the American Type Culture Collection (Rockville, MD), under the terms of the Budapest Treaty, and has been assigned accession number ATCC CRL9729.

A cell line of this type is potentially useful in replacement therapy in dysmyelinating diseases. Oligodendrocytes produced according to the present method can be assessed for their effectiveness in reversing (partially or completely) the effects of a genetic defect

-9-

which normally results in debilitation and death in animals in which the defect occurs. Murine mutants which have defective myelination in the central nervous system and/or the peripheral nervous system, can be used to investigate the effectiveness replacement therapy with conditionally immortalized precursor cell lines. Jaque, C. et al., Journal of Neurochemistry, 41:1335-1340 (1983). Survival of the animals or less severe effects of the dysmyelination will be evidence of correction of the defect.

Cell lines of the present invention, in which growth promoting gene expression is regulated, differ from currently available cell lines in which the immortalizing agent which establishes the cell line is not normally under external control. It is possible with this new technique to obtain proliferating cell lines which can be grown rapidly to large numbers and then cause these cells to become a differentiated derivative. Until development of the present method, it was difficult or impossible to obtain such derivatives (e.g., because they grow much less rapidly or do not grow at all).

The method of the present invention provides a means by which large numbers of differentiated cells can be produced. Cells conditionally immortalized by the method of the present invention have diagnostic and therapeutic applications. For example, if a large quantity of a specific type of differentiated cell is needed for use in diagnostic methods, for transplantation into an individual, or for use as a means of producing a desired product (e.g., protein, hormone, etc.), appropriate precursor (nondifferentiated) cells can be selected,

-10-

using known techniques. The progenitor cells can subsequently be modified by introduction of a growth promoting gene, such as an oncogene, then cultured under conditions in which the growth promoting gene is activated. When differentiated cells are needed, the cells are switched to conditions under which the growth promoting gene is inactivated. The previously undifferentiated cells are thereby altered, producing the desired differentiated cells.

05. 10. Alternatively, conditionally immortalized cells can be introduced (at a nonpermissive temperature) into an individual, in whom they will reside at the nonpermissive (i.e., body) temperature. The conditionally immortalized cells will then differentiate, thus providing an
15. "internal" source of the desired type of differentiated cell.

Recent work on central nervous system (CNS) transplants has been exciting and suggests rational approaches to therapy for CNS injury. Sladek, J.R. and
20. D.M. Gash, Neural Transplants: Development and Function, Plenum Press, N.Y. (1984). The work described herein is directly relevant to transplant studies. Methods developed to identify and count cells will be useful in analyzing the fate of transplanted cells or the behavior
25. of cells after injury (K. Frederiksen and R.D.G. McKay, 1988). The method disclosed in this invention which generates immortal cell lines that differentiate in vivo should be very important for cell replacement therapies.

30. Human JC virus infection is associated with the demyelinating disease, progressive multifocal leucoencephalopathy (PML). (ZuRhein, G.M., Prog. Med.

-11-

Virol., 11:185-206 (1969); Padgett et al., Lancet,
i:1257-1259 (1971); Padgett, B.L. and D.L. Walker, Prog.
Med. Virol., 22:1-34 (1976)). Transgenic mice have been
developed which express the early gene of the JC
05 papovavirus associated with PML. These animals fail to
myelinate their CNS (Small et al., 1986). This important
finding shows that the whole course of viral infection is
not necessary to cause disease - JC early gene expression
alone is sufficient. In JC virus infection early gene (T
10 antigen)-mediated disruption of oligodendrocyte
differentiation may occur either by the action of T
antigen directly in oligodendrocyte precursors or
indirectly in another cell type which regulates
oligodendrocyte differentiation.

15 Type 1 astrocytes are known to play an important
role in the differentiation of oligodendrocyte precursors
and are therefore candidates for the site of action of T
antigen function in causing PML. Noble, M. and K.
Murray, EMBO Journal, 3:2243-2247 (1984); Raff et al.,
20 Cell, 42:61-69 (1985). Retroviral vectors expressing
papovavirus T antigens have been shown capable of
immortalizing astrocytic precursors. Immortalized
astrocyte precursors can be used to produce large numbers
of differentiated astrocytes and, thus, used in the
25 production of oligodendrocytes.

Multiple sclerosis, while not clearly associated
with a virus, disturbs the differentiation of
oligodendrocytes (McKhann, G.M., Ann. Rev. Neurosci.,
5:219-239 (1982). The ability to infect and immortalize
30 cells of the early nervous system with papovavirus T
antigens provides an unusual opportunity to manipulate

-12-

cell types which interact to control oligodendrocyte differentiation.

Many neural tumors are histologically related to cells found in the early nervous system (Rubinstein, L.J., J. Neurosurg., 62:795-805 (1985). It is therefore crucial to characterize the factors controlling the differentiation of neural cells and to determine how oncogenes disrupt differentiation. This can be accomplished using the method and conditionally immortalized cells of the present invention.

The present invention will now be illustrated by the following Examples, which are not to be seen as limiting in any way.

EXAMPLE 1 Construction of retroviruses carrying oncogenes and a dominant selectable marker

pZipSV40tsA58

The recombinant retrovirus pZipSV40tsA58 was constructed by the insertion of the BglI - HpaI fragment of the temperature sensitive SV40 tsA58 early region into the BamHI site of the pZipNeosV shuttle vector in the sense orientation with respect to viral transcription. Cepko, C. et al., Cell, 37:1053-1062 (1984); Jat, P.S. et al., Molecular and Cellular Biology, 6:1204-1217 (1986); Jat, P.S. and P.A. Sharp, Journal of Virology, 59:746-750 (1986), the teachings of which are incorporated herein by reference. This SV40 fragment lacks both a promoter and polyadenylation sites. Consequently, transcription of T antigen sequences is exclusively initiated in the viral LTR. The recombinant plasmid was transfected into the

-13-

psi 2 helper cell line and neomycin resistant cell lines were derived by G418 selection. Mann, R. et al., Cell, 33:153-159 (1983), the teachings of which are incorporated herein by reference. These transfected cell lines secrete defective helper-free recombinant retroviruses carrying the thermolabile T antigen gene. The titre of recombinant virus was determined by infection of 3T3 cells. By growing these 3T3 cell lines at 33° and 39°C, it was determined by immunohistochemistry and immunoprecipitation that they synthesize a ts form of SV40 T antigen. Culture medium from one of the highest titre psi 2 lines, psi2SVtsA58-4 (10^4 neo.resistant 3T3 units/ml.), was the source of virus for the infection of primary cultures of rat neural cells.

The target cells for viral infection were derived from the E18 entorhinal cortex and the P 2 cerebellum. The cells were dissociated by incubation in PBS, 0.5 mm EDTA, 0.25% trypsin, at 37°C for 20-30 minutes. The trypsin solution was removed and replaced with DMEM, 10% fetal bovine serum. The cells were trituated by 10-20 passages through a narrow bore pasteur pipette. The cell suspension was plated onto polyornithine coated tissue culture dishes at a density of 10^5 cells/cm². Cell survival was greater than 70%, as determined by fluorescein diacetate uptake. Several schedules were examined for the optimal time of infection from infection in suspension, from 0 hrs. to 1 week post dissection. 4-12 hours after plating was found to yield the largest number of neo resistant colonies. Infection was achieved by replacing the culture medium on the attached cells

-14-

with a small volume (0.8 ml./10 cm. dish) of sterile medium from the producer line psi2SVtsA58-4 containing 8 microgm./ml. of polybrene. The cells were incubated for 2 hours at 37°C. 8-10 volumes of 50-50 medium were then added and the cells plated at 33°C. The medium was changed the following day and four days postinfection, when selection for infected, neo resistant cells was initiated by the addition 0.2 mg./ml. G418 SO₄ (Geneticin, GIBCO). Cell death became apparent after 1 week of selection. Living colonies remained present in uninfected controls for as long as 1 month after the application of G418 selection. Resistant colonies were picked when they contained approximately 1000 cells. In general, primary embryonic brain cultures gave ten to thirty fold fewer colonies than a similar number of NIH 3T3 cells.

Cultures were passaged at high density and fed twice weekly. The 50/50 growth medium contained DMEM, 5% F.C.S., 2.5 microg./ml. insulin, 10 nm. progesterone, 10 pm. beta-estradiol, 1 microg./ml. transferrin, 0.1 nm. putrescine, 30 nm. sodium selenite, 0.3 nm. triiodothyronine, 20 nm. hydrocortisone, 2 mm. sodium pyruvate.

Other retroviruses can also be constructed, as described below.

Construction of pZipSV40 (U19) tsA58

Paucha et al. described a variant of SV40 T antigen (U19) which was deficient in certain viral functions, but has recently been shown to have enhanced ability to immortalize primary fibroblasts. Paucha, E. et al.,

-15-

Journal of Virology, 57:50-64 (1986); Jat, P.S. et al.,
Molecular and Cellular Biology, 6:1204-1217 (1986), the
teachings of which are incorporated herein by reference.
The U19 and tsA58 mutations fall in different parts of
large T antigen. A retrovirus double mutant with both
increased immortalization efficiency and thermolability
has been constructed, as described in Example 3.

pZipPytsA (1T)

Because cell culture suggests that the polyoma large
T antigen has a less powerful effect on the immortalized
cells than SV40 T antigen, a retrovirus carrying the
transforming early gene of polyoma virus can also be
constructed and should be useful. Polyoma virus large T
antigen immortalized primary fibroblasts are not
transformed by supertransduction with the ras oncogene.
In contrast, the ras oncogene will transform primary
fibroblasts that have been immortalized with the SV40 T
antigen. This result shows that polyoma and SV40 large T
antigens interact with primary fibroblasts in different
ways. One interpretation is that polyoma large T is
'milder' and this mild effect may be an advantage from
the point of view of using the oncogenes for precursor
cell immortalization. A temperature sensitive variant of
mouse polyoma large T antigen is available. Fried, M.,
Proceedings of the National Academy of Sciences, USA,
53:486-542 (1965).

Unlike SV40 early region, the early region of
polyoma virus encodes two proteins with oncogenic
properties. The middle T protein is transforming and the
large T protein immortalizing. A useful retrovirus will
contain only the sequences necessary for the large T

-16-

antigen and the tsA form of this protein. A plasmid carrying the wild type large T antigen cDNA and a second plasmid carrying the entire tsA early region have been constructed and generously provided by Dr. R. Kamen (Genetics Inst.). The region carrying the altered DNA sequences which confer thermolability can be placed into the large T antigen cDNA and a retrovirus constructed.

pZipJCtsA

Evidence from transgenic mice shows that the human polyoma virus T antigen disrupts the differentiation of oligodendrocytes and may account for the demyelination found in the disease progressive multifocal leucoencephalopathy (PML). Papovavirus oncogenes, such as those derived from the three closely related viruses mouse polyoma, monkey SV40 and human JC can be used to construct a retrovirus. For example, the polyoma and SV40 thermolabile sequences can be placed onto the JC virus large T antigen.

EXAMPLE 2 Immortalization of Cerebellar Cells

Three different oncogenes, SV40 T antigen, v-myc and neu were tested for their ability to establish cell lines from the developing cerebellum. Materials and procedures used were as follows:

Markers used to identify precursor populations

Prior to establishing cell lines from the postnatal cerebellum, the proliferating cells which are potential targets for retroviral mediated gene transfer were identified. Three classes of antibody were used as

-17-

markers to define the proliferative status of different cell types in the postnatal cerebellum: the monoclonal antibody Rat 401, anti-vimentin and anti-GFAP antibodies.

The monoclonal antibody Rat 401 recognizes a
05 transient population of embryonic columnar epithelial
cells and radial glial cells in many regions of the rat
CNS. Hockfield, S. and R. McKay, Journal of
Neuroscience, 12:3310-3328 (1985). The antibody
recognizes a 200 Kd. protein and some smaller peptides
100 which are variably found and may be degradation products.
Known methods of measuring total cell numbers in the rat
CNS during development were used with immunohistochemi-
stry and techniques for labelling proliferating cells to
show that Rat 401 recognized a major population of
15 proliferating neuronal precursor cells in the spinal
cord. Frederiksen, K. and R. McKay, J. Neurosci. (1988).
In primary culture of embryonic brain cells a transient
co-expression of the Rat 401 antigen and either
neurofilaments or the astrocytic intermediate filament
20 protein, GFAP, was seen in morphologically distinct cell
types. These data suggest that the Rat 401 positive
population contains precursors to both neurons and
astrocytes. It has previously been shown in the
cerebellum that the monoclonal antibody Rat 401
25 recognized a transient cell population. Hockfield, S.
and R. McKay, J. Neurosci., 5:3310-3328 (1985). These
studies support the use of the Rat 401 antigen as an
assay for precursor cell lines.

Vimentin is found in the precursor cells to the
30 cerebellar granule neurons (Bovolenta, P. et al., Dev.
Biol., 102:248-259 (1984) as well as neuronal and glial

-18-

precursor cells elsewhere in the nervous system.

Vimentin is not generally found in mature neurons and astrocytes in vivo. About the time neurons become postmitotic, they begin to synthesize a specific set of intermediate filament proteins, neurofilaments, and lose vimentin expression.

Glial fibrillary acidic protein (GFAP) is the core intermediate filament protein which replaces vimentin in astrocytes (reviewed in Fields, 1985). This protein is expressed in the adult cerebellum in the radial Bergman glial cells and in astrocytes. GFAP is also found in some cells of the germinal zone of the monkey neuroepithelium during neurogenesis (Levitt, P. et al., J. Neurosci., 1:27-39 (1981). These immunohistochemical observations and our quantitation of cell populations in vivo (Frederiksen, K. and R. McKay, J. Neurosci., (1988)) suggested that there was a proliferating glial precursor cell which was Rat 401 negative and GFAP positive.

As Rat 401 antigen, vimentin and GFAP are potential markers for distinct precursor populations, the differential expression of these antigens was used to characterize cell populations in the postnatal cerebellum. Dissociated cerebellar cells were stained with Rat 401, anti-vimentin and anti-GFAP antibodies. The proportion of Rat 401 positive cells declines to zero before postnatal day 15 (P15), showing that Rat 401 is a precursor cell marker and confirming previous immunohistochemical analysis of cell differentiation in the postnatal cerebellum. The proportion of vimentin positive cells is much larger than the proportion of Rat 401 positive cells but also declines over this period.

-19-

The proportion of GFAP positive cells is initially lower than the proportion of Rat 401 positive cells but by the end of the second postnatal week the number of GFAP positive cells increases while the expression of Rat 401 is lost.

These three markers are differentially expressed in cerebellar cell populations but further data is needed to establish if these cell populations are independent of one another and actively proliferating. The overlap in cell populations was determined by double label immunohistochemistry (Table 1) and the proliferative status of the antigenically distinct cell types was measured by an in vivo pulse of tritiated thymidine followed by immunohistochemistry and autoradiography on dissociated cells (Table 2).

Double immunohistochemistry showed that the Rat 401 positive population was a subset of the vimentin population but the autoradiographic data shows that these two populations are not in identical proliferative states. The GFAP positive population and the vimentin positive populations also overlap.

Animals, cell lines and antibodies

Sprague Dawley rats were obtained from Taconic Inc., N.Y. NIH 3T3 cells and psi2 cells lines were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) calf serum, penicillin and streptomycin. The anti-vimentin antibody was obtained from ICN (Cat. No. 69-127), the anti-GFAP antibody was obtained from ICN (Cat. No. 69-110), and the anti-neurofilament antibody was Sternberger-Meyer (Cat. No. SMI 31), the Rat 401

-20-

antibody was established in this group and has been previously described (Hockfield, S. and R. McKay, J. Neurosci., 5:3310-3328 (1985)), the anti-T antibody was monoclonal antibody 412 prepared by E. Harlow, the
05 anti-Gal C antibody has been previously described Ranscht et al., 1982. In double label experiments rabbit anti-vimentin was obtained from R. Hynes, the rabbit anti GFAP from L. Eng., the rabbit anti-neurofilament was purchased from ICN (Cat. No. 20074). Secondary
10 antibodies were obtained from Cappel-Worthington.

Analysis of cerebellar cells types in vivo

A detailed description of dissociation protocols, autoradiographic procedures and control experiments for cell numbers and staining procedures can be found in
15 Frederiksen, K. and R. McKay, J. Neurosci. (1988). The cerebellum was dissected from postnatal rats and the cells dissociated by trituration after digestion in 0.15% trypsin in Ca^{++} and Mg^{++} free phosphate buffered saline. Measured aliquots of the dissociated cell suspension were
20 spun onto coverslips and stained with primary antibodies and either fluorescein, rhodamine or peroxidase conjugated second antibodies. The data shown was derived from four or more animals from two or more litters.

Primary cultures and infection protocols

25 The cerebellum was removed from P2 animals and incubated in 0.08% trypsin for 30 minutes at 37°C. After further dissection into small pieces the cells were dissociated by trituration in DMEM, 10% fetal calf serum using a 20 microlitre pipette. The cell suspension

-21-

was plated onto polyornithine coated tissue culture dishes (15 micrograms/ml, Sigma) in DMEM, 10% fetal calf serum and incubated at 37°C 24 hours after plating the cells were infected for 2 hours with the recombinant
05 retroviruses in 8 micrograms/ml (Aldrich). After infection the virus containing medium was replaced with fresh DMEM, 10% fetal calf serum. tsA58 infected cell lines were subsequently grown at 33°C. 48 hours after infection the cultures were passaged and subjected to
10 selection in 0.2 micrograms/ml G418 (Geneticin, Gibco). The medium was changed with fresh G418 every 3-4 days. Within three weeks control uninfected dishes had very few remaining cells and the infected dishes had macroscopic G418 resistant colonies. Colonies were picked using
15 cloning rings and expanded into 96 well plates.

Growth and characterization of cell lines

The cells were continually grown in DMEM and 10% fetal calf serum. The neu infected cells could be expanded and frozen but always grew slowly. The v-myc
20 and T-antigen derived cells grew rapidly for a year and were subcloned. The immunohistochemical analysis of antigen expression in St15A cells was carried out in DMEM and selected batches of fetal calf serum at 33°C and 39°C. The immunoblotting procedure was as described by
25 Twobin et al. (1979). Analysis of proviral DNA was carried out on high molecular weight DNA prepared by the method Shih and Weinberg (1982) and fractionated on 0.8% agarose gels. The DNA was transferred to Zeta Bind (CUNO Labs, Meriden, Conn.) and hybridized by standard methods.
30 Southern, 1975; Maniatis et al., Molecular Cloning: A

-22-

Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982). The serum free medium used was the N2 medium of Bottenstein and Sato (1979). The co-cultures were carried out after labelling the immortal cells with either fluorescein succinimidylester (Bronner-Fraser, M., Journal of Cellular Biology, 101:610 (1985)), the carbocyanine dye diI (Honig, M.G. and R.I. Hume, Journal of Cellular Biology, 103:171-187 (1986)) or rhodaminated latex beads (Katz et al., 1984). These labelled cells were then added to primary cultures of E14 cerebral cortex or P2 cerebellum one day after the primary cells were plated. The double label experiments with Rat 401 and rabbit anti-neurofilament antibody used the cross reaction between anti-MSH antibody and neuro-filament analyzed by Verhaagen et al. (1986).

v-myc and SV40 T antigen have previously been shown to be efficient in establishing rodent fibroblast cell lines. Land, H. et al., Nature, 304:596-602 (1983); Jat and Sharp, Molecular and Cellular Biology, 6:1204-1217 (1986). In contrast, the neu oncogene has not previously been shown to establish primary rodent cell lines. However, activated neu is associated with neuroblastomas and glioblastomas (Schechter, A.L. et al., Nature, 312:513-516 (1984)) and the cellular neu is known to be transcribed and translated in the early nervous system. SV40 virus has been shown to generate cell lines with either neuronal or glial properties (DeVitry, F. et al., Proceedings of the National Academy of Sciences, USA, 77:4165-4169 (1974); Neto, V.M. et al., Dev. Brain Res., 26:11-22 (1986)).

-23-

Details of the construction of the v-myc transducing retrovirus can be found elsewhere (Dotto et al., 1986). The neu transducing retrovirus was a generous gift of Dr. C.I. Bargmann. SV40 T antigen has another advantage in that it is available in a tight temperature sensitive form, making it possible to switch off the function of the oncogene by raising the temperature of cell growth. Tägtmeyer, P., Journal of Virology, 15:613-618 (1985); Tägtmeyer, P., In: J. Tooze (ed.), Molecular Biology of Tumor Viruses (2d ed.), Cold Spring Harbor Laboratory, pp. 297-338 (1980). A transducing retrovirus carrying the tsA58 mutant form of SV40 large T antigen was constructed (Figure 1 and Example 1). The ability to externally regulate the function of the growth promoting gene makes it possible to determine if a precursor cell line can differentiate in the absence of the immortalizing gene function.

The three recombinant retroviruses described were all constructed by inserting DNA sequences encoding the oncogenes into the unique BamHI site of the pZipNeoSV(X)1 vector (Figure 1); the genes were inserted in the sense orientation with respect to retroviral transcription driven by the cis-acting transcriptional regulatory sequences in the left-hand long terminal repeat (LTR). Previous work has shown that different regulatory sequences allow the same oncogene to interact with different cell types. Because the only differences in the three retroviruses used here were in the coding sequences, any differences in the derived cell lines must be due to the oncogenes themselves and not to the regulatory sequences controlling transcription. All the

-24-

pZipNeoSVtsA58 producer cell lines were shown to synthesize virus which only transduce large T antigen. Thus the reported enhancement of transformation by SV40 small T antigen (Bikel et al., 1987) is not a complicating factor here.

Properties of Cerebellar Cell Lines

To be a candidate for immortalization, a cell type must be both present and proliferating in primary culture. The antigenic and proliferative status of P2 cerebellar cells in dissociated tissue culture was measured by immunohistochemistry and thymidine autoradiography. Rat 401 positive cells are present in short term primary culture. The number of cells expressing GFAP is very low. The immunohistochemical data also shows that vimentin positive cells are present in primary culture. Antigenic and autoradiographic double label showed that Rat 401 positive and vimentin positive cells proliferate in primary culture but the GFAP positive cells are quiescent.

After infection and selection, isolated colonies were picked. Cell lines were characterized immunohistochemically with Rat 401, anti-GFAP and anti-vimentin antibodies. As shown in Table 3, all but one of the derived cell lines were Rat 401 positive and all were vimentin positive. GFAP expression was found in all of the cell lines derived from myc and neu infection; in contrast the SV40 immortalized cell lines were GFAP negative at the permissive temperature. These results show that it is possible to obtain cell lines expressing

-25-

markers characteristic of three proliferating populations defined in Tables 2 and 3.

-26-

TABLES

Table 1.

Proportion of Rat 401 and GFAP positive P3 cerebellar cells double labelled with other antibodies.

05	Rat 401 +,	96 %	vimentin +
	Rat 401 +,	53 %	GFAP +
	GFAP +,	77 %	Rat 401 +
	GFAP +,	80 %	vimentin +

Table 2.

10 Proportion of antibody labelled cells which are also radiolabelled by an in vivo pulse of tritiated thymidine two hours before cell dissociation.

Antibody	% cells radiolabelled on postnatal day				
	2	7	9	12	15
-15 Rat 401	8	8	9	-	-
vimentin	17	16	20	21	25
GFAP	9	11	10	6	5

Table 3.

Antigenic profile of cerebellar cell lines.

Immortalizing gene	No. of lines	Primary antibodies		
		Rat 401	Vimentin	GFAP
20 SV40tsA58	9	+	+	-
	1	-	+	-
25 v-myc	31	+	+	+
neu	4	+	+	+

-27-

Two of the SV40 cell lines were grown at 33°C and 39°C and immunohistochemically analyzed for differentiation. The ST15I cell line was Rat 401 negative and did not differentiate at 39°C in fetal calf serum. The ST15A line was used as a representative of the Rat 401 positive class. The results for AT15A show, as expected, that at the nonpermissive temperature, the cells lose T antigen expression. At the elevated temperature, these cells also lose Rat 401 antigenicity and gain GFAP expression. This antigenic switch in the cells is remarkably complete. At 33°C Rat 401 negative cells or GFAP positive cells occur with a frequency of less than 10^{-3} at 33°C. After several days at 39°C, the majority (95%) of the ST15A cells were Rat 401 negative and GFAP positive. An increase in GFAP expression was confirmed by immunoblotting of total proteins extracted from cells grown at the permissive and nonpermissive temperature. Immunoblotting also showed that T antigen levels fall at the non-permissive temperature. The large cultures necessary for protein chemistry differed from the analytical cultures used for the immunohistochemical analysis as Rat 401 expression remained in 25% of the cells after 10 days of growth at the elevated temperature. Vimentin levels were unchanged.

ST15A were grown in the N2 medium of Bottenstein and Sata (1979). After 5 days at 39°C, cells with a neuronal morphology, which react with the antineurofilament monoclonal antibody SMI 31, were seen. After nine days in N2 medium, the proportion of SMI 31 positive cells increased (to 90% in some cultures) and cells with very long neurites (greater than 300 microns) were present.

-28-

Cells with this highly distinctive neuronal morphology were present both at 33°C and 39°C.

When live ST15A cells grown in 10% fetal calf serum were stained with an anti-galactocereberoside monoclonal antibody, approximately 1% of the cells were positive. The labelling of live cells and the distribution of the antigen shows that this is a surface component that is recognized by the anti-gal C antibody. The frequency of anti-GaIC labelled cells was enhanced when ST15A cells were grown at the non-permissive temperatures. Galactocereberoside expression has been extensively used as a marker for commitment to oligodendrocyte differentiation (Raff, M.C. et al., Nature, 274:813-186 (1978), 1979; Schachner, M. and M. Willinger, In: The Menarini Series of Immunopathology, Vol. 2, pp. 37-60 (1979).

As the mechanisms controlling the differentiation of the neuroepithelium depend on cell interaction, differentiation of tsA cerebellar cell lines upon co-cultivation with primary embryonic brain cells was assessed. To identify the clonal immortal cells in the presence of primary cells, they were first labeled internally with either the succinimidyl ester of fluorescein (Bronner-Fraser, M., Journal of Cellular Biology, 101:610 (1985)) or the lipid soluble carbocyanine dye diI (Honig, M.G. and R.I. Hume, Journal of Cellular Biology, 103:171-187 (1986)). These internally labelled cells were then analyzed after they were added to primary rat cultures. The primary cells were derived from either the E14 cerebral cortex or from postnatal day 3 cerebellum. The mixed cultures were

-29-

processed immunohistochemically with anti-T,
anti-neurofilament, anti-vimentin, anti-GFAP, Rat 401 and
the appropriate second antibody, tsA immortalized cells
were identified by the internal label and the binding of
05 antibody established in the same cell.

The initial experiments using this paradigm were
carried out at 33°C because the red nuclear T antigen
fluorescence serves as a control for the internal
labelling method. No internally labelled T antigen
10 negative cells were seen. Confidence in these results is
high because for each antibody there are large numbers of
primary cells which are not internally labelled which
acts as controls for the specificity of antibody stain-
ing.

15 In the presence of primary brain cells ST15A, cells
can lose vimentin and Rat 401 antigenicity and gain
either GFAP or neurofilament reactivity. Three different
lines of evidence suggest that ST15I can differentiate
into neurons: Firstly, many of the fluorescein labelled
20 cells adopt a morphology of small cell bodies with
multiple processes. Secondly, like primary neurons these
small ST15I cells are often found in clumps over flat
non-neuronal cells. Thirdly, the processes of these
small ST15I cells can be stained with an
25 anti-neurofilament monoclonal antibody. ST15I cells
which express the Rat 401 antigen were also found in
co-culture. In the Rat 401 positive ST15I cells shown,
the antigen is restricted to a small perinuclear region.
This distribution is also characteristically found in
30 primary neuroepithelial cells as they differentiate from

-30-

the Rat 401 positive precursor state to the neurofilament positive differentiated neuron.

Cells with neuronal properties were also produced when the v-myc induced cell line M15B was treated with dibutryl cyclic AMP and retinoic acid. This induction is not complete, but characteristically occurs in a colonial manner, suggesting that a commitment step occurs in a proliferating cell which subsequently differentiates into neurons or that local interactions are important in neuronal induction.

Southern blot analysis was used to determine whether the cell lines were clonal, panel A was hybridized with SV40 probe and panel B with neomycin probe. The SV40 sequences were released from flanking DNA by Bam HI digestion yielding a 2.3 Kb fragment designated b. The size of this fragment is too small to encode the small t antigen transcript and confirms the immunohistochemistry and immunoblotting data, showing that the pZipSVtsA58 retrovirus transduces large T antigen. Xba cuts in the viral LTR sequences releasing a single full length proviral sequence from ST15A and ST15I. EcoRI and Bgl II digestion cuts once in the provirus, yielding only a single fragment in ST15A and ST15I containing SV40 sequences and flanking cellular DNA. This data demonstrates that the ST15A and ST15I cells carried only a single insertion. In contrast, the M15b cells showed two large neomycin complementary bands. These two bands are found in the same ratios in multiple subclones of M15B suggesting that the M15B cell line as two independent viral insertion sites and is also a clonal cell line.

-31-

The present data suggests that the use of the tsA58 variant of SV40 T antigen favors the differentiation of the multipotential brain precursor cell at the non-permissive temperature of 39°C. The core body temperature of the rat is 39°C, suggesting that ts cell lines may differentiate when transplanted into the developing CNS. Wild type T immortalized cells have been transplanted into the immediately postnatal CNS of the rat. Results showed that as many as one million cells can be placed in the CNS, where they remain for several months without any gross indication of tumor formation (McKay et al., 1988). Transplantation of conditionally immortalized cell lines into the developing nervous system offers the most rigorous assay for the differentiation potential of these cell lines. Transplantation of primary neuroepithelium into the lesioned adult CNS has been used to restore behavioral function to lesioned animals. It may be possible to use cell lines in place of primary cells allowing a detailed analysis of the molecular genetics of behavioral recovery.

Example 3 Infection of optic nerve primary cultures with retrovirus ts U19

1. Optic nerve from 4-6 rats (P4) were dissociated according to the following protocol:
 - i) The nerves were placed in 2 ml of Basal Eagles Medium (BEM) with 0.02M Hepes (Sigma, T5391) and collagenase 0.02% (Sigma, type IV, C5138) for 15 minutes at 37°C.

-32-

- ii) The BEM was then removed and 2 ml of HBSS, Cs^{++} and Mg^{++} "free" and 0.25% trypsin were added for 15 minutes at 37°C (40X, Sigma T0511)
- 05 iii) Cells were checked to determine whether they had begun to dissociate. Step i) and ii) were repeated, as required.
- iv) 1 ml of media was removed and 1 ml of Dulbecco's Modified Eagles Medium (DMEM).10%FCS was added. The nerves were panned up and down 10 3-5X through an 18 gauge needle with a 2 ml syringe. This was repeated three times through a 21 gauge needle.
- v) Large pieces of nerve were removed and the cell suspension was centrifuged to remove the 15 digestion enzyme.
- vi) The pellet was resuspended in DMEM with 10% fetal calf serum (FCS) and were plated on polyornithine-covered dishes.
2. One or two days after dissociation, the medium was 20 replaced with psi 2 supernatant (producer cells). 2 ml of medium (10^4 - 10^5 cfu/ml.) were added to each 2.5 cm dish. Polybrene (Sigma, P4S15) was also added to each dish, to a final concentration of 8 ug/ml. Cells were incubated at 33°C for 2-3 hrs.
- 25 3. The virus-containing medium was removed and replaced with 2.5 ml of BMEM/10% FCS (same as in Step 1 vi).

-33-

4. Two days later, the infected cells were split 1:2 to 1:5. At this time G418 (Geneticin, Sigma G9516) was added to 200 micrograms/ml).
5. The medium was changed every 4.5 days and G418 was kept at the same concentration. Colonies began to form between 2-3 weeks later.

Cloning cell lines

1. 24 well petri dishes were treated with pOrn.
2. Cloning rings (glass, 7 mm ϕ and about 7 mm height) were placed with high vacuum gresse (Down Corning from Dupont) on a colony and 30-100 lambda of 1X trypsin/EDTA was added. Detachment of cells was checked under a microscope and cells were dissociated with 200 lambda pipetor and transferred to 24 wells/dish.
3. The clones were then assayed for the markers described previously.

Construction of plasmid (pZip tsa 58 U19 or pts U19)

The plasmid pZiptsa58U19 or ptsU19 is represented in Figure 2. U19 is a variant of SV40 T antigen, described by Paucha and co-workers. Paucha, E. et al., Journal of Virology, 57:50-64 (1986). The U19 and tsA58 mutations occur in different parts of the large T antigen; Paucha et al. describe mutation of the large T antigen sequence from serine (amino acid position 152) and arginine (amino

-34-

acid position 154) to, respectively, asparagine and lysine in the U19 mutant.

- 05 1. The tsA58 temperature sensitive form of the SV40 T antigen was placed in the pZipNeo SV (X)1 vector by inserting the whole early region (BglI-HpaI) of tsA58 into the Bam HI site.
22. The hybrid of the SV40 T antigen gene, tsU19, was constructed using the pZip tsA58 and the U19 mutant.

Equivalents

- 10 15 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

-35-

CLAIMS

1. A method of producing differentiated cells,
comprising culturing appropriate precursor cells,
having incorporated therein a growth-promoting gene
05 whose activation or inactivation is controlled by an
external factor, under conditions which activate
said growth-promoting gene; maintaining said
precursor cells under appropriate conditions and for
sufficient time for growth of said precursor cells;
10 and inactivating said growth-promoting gene by
shifting to conditions which inactivate said growth-
promoting gene.
2. Differentiated cells produced by the method of Claim
1.
- 15 3. A method of immortalizing a cell line, to produce
differentiated cells, comprising:
 - a. introducing into appropriately-selected
precursor cells in primary culture, under
permissive conditions, a growth-promoting gene
20 which is activated under said permissive
conditions, said growth-promoting gene
conferring on precursor cells the ability to
grow in tissue culture, to produce cells
containing said growth-promoting gene;
 - 25 b. selecting cells containing said
growth-promoting gene and maintaining them
under permissive conditions and in medium

-36-

appropriate for cell growth, for sufficient time for cell growth;

- 05 c. shifting conditions in (b) to nonpermissive conditions, to inactive said growth promoting gene, and maintaining the cells under conditions appropriate for cell growth and differentiation to occur.

4. Differentiated cells produced by the method of Claim 3.

- 10 5. A method of producing differentiated cells, comprising:

- 15 a. introducing into appropriately-selected precursor cells a retroviral vector comprising a growth-promoting gene which is the temperature-sensitive domain of the tsA58 strain of the SV40 virus;

- b. culturing cells produced in (a) at a temperature of approximately 33°C and under conditions sufficient for cell growth;

- 20 c. shifting the temperature of the cultured cells to approximately 39°C; and

- d. maintaining the cells under conditions appropriate for and for sufficient time for cell differentiation to occur.

- 25 6. Differentiated cells produced by the method of Claim 5.

-37-

7. A method of immortalizing cells from the embryonic nervous system, comprising:
 - a. selecting appropriate precursor cells;
 - b. introducing into precursor cells in primary
05 culture a retrovirus comprising the temperature sensitive domain of the tsA58 strain of the SV40 virus and a gene encoding drug resistance;
 - c. selecting drug resistant cells and maintaining
10 them under conditions appropriate for cell growth and at a temperature of approximately 33°C, for sufficient time for cell growth to occur; and
 - d. shifting the temperature to approximately 39°C.
8. The method of Claim 7 wherein the precursor cells
15 are derived from embryonic hippocampus or from embryonic cerebellum.
9. An immortalized cell line produced by incorporating
20 into appropriate precursor cells a growth-promoting gene which enables the cells to grow and is controlled by an external factor.
10. An immortalized cell line produced by incorporating
25 into embryonic nervous system cells a retroviral vector comprising a growth-producing gene which is the temperature-sensitive domain of the tsA58 strain of the SV40 virus and a gene encoding drug resistance, culturing said cells at a temperature of approximately 33°C under conditions sufficient for and for sufficient time for cell growth to occur and

-38-

subsequently culturing said cells under appropriate conditions and at a temperature of approximately 39°C.

- 05 11. A recombinant retrovirus, comprising the pZipNeoSV shuttle vector having inserted into its BamHI site, in a sense orientation with respect to viral transcription, the BglII to HpaI fragment of the SV40 tsA58 early region, the BglII to HpaI fragment
10 consisting essentially of nucleotides 5235 to 2666 of the SV40 tsA58 early region.
12. A recombinant retrovirus of Claim 11, wherein the BglII to HpaI fragment of the SV40 tsA58 early region comprises, in addition to the tsA58 mutation of the
15 large T antigen gene, a further mutation in the large T antigen gene, the mutation occurring in the region of the large T antigen gene which encodes amino acids 106 to 158 of the large T antigen.
- 20 13. A recombinant retrovirus, comprising the pZipNeoSV shuttle vector having inserted into its BamHI site, in a sense orientation with respect to viral transcription, a hybrid SV40 T antigen gene, the hybrid SV40 large T antigen gene comprising a first
25 mutation which is a temperature sensitive mutation of the large T antigen gene and a second mutation which is a mutation in the region of the large T antigen gene which encodes amino acids 106 to 158 of the large T antigen.

-39-

14. A recombinant retrovirus of Claim 13 wherein the first mutation is the tsA58 mutation of the large T antigen gene and the second mutation is the U19 mutation.
- 05 15. A recombinant retrovirus, comprising the pZipNeoSV shuttle vector having inserted into its BamHI site, in a sense orientation with respect to viral transcription, a hybrid SV40 T antigen gene which is a BglII to HpaI fragment of the SV40 tsA58 early
10 region comprising nucleotides 5235 to 2666 and the U19 mutation.
16. The oligodendrocyte optic nerve cell line, ts U195, deposited at the American Type Culture Collection under accession number CRL9729.




FIG. 1

pZIP-Neo SV(X)I




FIG. 2A




FIG. 2B

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 89/01526

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : C 12 N 5/00, C 12 N 15/00, C 12 N 7/00														
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> Classification System IPC⁴ </div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> Classification Symbols C 12 N </div> </td> </tr> </table> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched ⁸ </div>			<div style="border: 1px solid black; padding: 5px;"> Classification System IPC⁴ </div>	<div style="border: 1px solid black; padding: 5px;"> Classification Symbols C 12 N </div>										
<div style="border: 1px solid black; padding: 5px;"> Classification System IPC⁴ </div>	<div style="border: 1px solid black; padding: 5px;"> Classification Symbols C 12 N </div>													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; font-size: small;">Category ⁹</th> <th style="width: 70%; font-size: small;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; font-size: small;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;"> Virology, vol. 127, no. 1, 1983, Academic Press, Inc., C.A. Petit et al.: "Immortalization of rodent embryo fibroblasts by SV40 is maintained by the A gene", pages 74-82, see the whole article <div style="text-align: center;">--</div> </td> <td style="vertical-align: top;">1-7,9,10</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X,P</td> <td style="vertical-align: top;"> Biological Abstracts/RRM, vol. 36, G. Almazan et al.: "Immortalization of an oligodendrocyte precursor cell via a retrovirus carrying a temperature sensitive oncogene", abstract no. 28937, & 18th Annual Meeting of the Society for Neuroscience, Toronto, Ontario, CA, 13-18 November 1988, Soc. Neurosci Abstr 14 (2). 1988. 1130, see the whole abstract <div style="text-align: center;">--</div> </td> <td style="vertical-align: top;">1-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;"> Molecular and Cellular Biology, vol. 6, no. 4, April 1986, American Society for Microbiology, <div style="text-align: right;">./.</div> </td> <td style="vertical-align: top;">11-15</td> </tr> </tbody> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	Virology, vol. 127, no. 1, 1983, Academic Press, Inc., C.A. Petit et al.: "Immortalization of rodent embryo fibroblasts by SV40 is maintained by the A gene", pages 74-82, see the whole article <div style="text-align: center;">--</div>	1-7,9,10	X,P	Biological Abstracts/RRM, vol. 36, G. Almazan et al.: "Immortalization of an oligodendrocyte precursor cell via a retrovirus carrying a temperature sensitive oncogene", abstract no. 28937, & 18th Annual Meeting of the Society for Neuroscience, Toronto, Ontario, CA, 13-18 November 1988, Soc. Neurosci Abstr 14 (2). 1988. 1130, see the whole abstract <div style="text-align: center;">--</div>	1-16	A	Molecular and Cellular Biology, vol. 6, no. 4, April 1986, American Society for Microbiology, <div style="text-align: right;">./.</div>	11-15
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	Virology, vol. 127, no. 1, 1983, Academic Press, Inc., C.A. Petit et al.: "Immortalization of rodent embryo fibroblasts by SV40 is maintained by the A gene", pages 74-82, see the whole article <div style="text-align: center;">--</div>	1-7,9,10												
X,P	Biological Abstracts/RRM, vol. 36, G. Almazan et al.: "Immortalization of an oligodendrocyte precursor cell via a retrovirus carrying a temperature sensitive oncogene", abstract no. 28937, & 18th Annual Meeting of the Society for Neuroscience, Toronto, Ontario, CA, 13-18 November 1988, Soc. Neurosci Abstr 14 (2). 1988. 1130, see the whole abstract <div style="text-align: center;">--</div>	1-16												
A	Molecular and Cellular Biology, vol. 6, no. 4, April 1986, American Society for Microbiology, <div style="text-align: right;">./.</div>	11-15												
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>¹⁰ * Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 26th July 1989 </div> </td> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: large;">22 AUG 1989</div> </div> </td> </tr> <tr> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> International Searching Authority EUROPEAN PATENT OFFICE </div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer M. VAN MOL </div> </td> </tr> </table>			<div style="border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 26th July 1989 </div>	<div style="border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: large;">22 AUG 1989</div> </div>	<div style="border: 1px solid black; padding: 5px;"> International Searching Authority EUROPEAN PATENT OFFICE </div>	<div style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer M. VAN MOL </div>								
<div style="border: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 26th July 1989 </div>	<div style="border: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: large;">22 AUG 1989</div> </div>													
<div style="border: 1px solid black; padding: 5px;"> International Searching Authority EUROPEAN PATENT OFFICE </div>	<div style="border: 1px solid black; padding: 5px;"> Signature of Authorized Officer M. VAN MOL </div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	<p>P.S. Jat et al.: "Recombinant retro-viruses encoding Simian Virus 40 large T antigen and polyomavirus large and middle T antigens", pages 1204-1217, see the whole article</p> <p>cited in the application</p> <p>-----</p>	